{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T17:57:06Z","timestamp":1794506226157,"version":"4.9.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Orion Corporation and Orion Pharma"},{"DOI":"10.13039\/501100024580","name":"Orion Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024580","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.eururo.2025.05.037","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T07:30:32Z","timestamp":1750404632000},"page":"400-407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial"],"prefix":"10.1016","volume":"88","author":[{"given":"Marc-Oliver","family":"Grimm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Littleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noman","family":"Paracha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Verholen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.05.037_b0005","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.05.037_b0010","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.05.037_b0015","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00a0\u00d7\u00a02 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.05.037_b0020","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.05.037_b0025","first-page":"1696","article-title":"Abiraterone in metastatic prostate cancer","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.05.037_b0030","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.05.037_b0035","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.05.037_b0040","series-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer","author":"Cornford","year":"2024"},{"key":"10.1016\/j.eururo.2025.05.037_b0045","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2025.05.037_b0050","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO Guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.05.037_b0055","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.05.037_b0060","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.05.037_b0065","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.05.037_b0070","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.eururo.2025.05.037_b0075","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.3390\/cancers13184522","article-title":"Optimal sequencing and predictive biomarkers in patients with advanced prostate cancer","volume":"13","author":"Cattrini","year":"2021","journal-title":"Cancers"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2025.05.037_b0080","doi-asserted-by":"crossref","first-page":"S1162","DOI":"10.1016\/j.annonc.2022.07.1492","article-title":"1360MO Quality of life and patient-relevant endpoints with darolutamide in the phase III ARASENS study","volume":"33","author":"Fizazi","year":"2022","journal-title":"Ann Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2025.05.037_b0085","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1200\/JCO.2022.40.6_suppl.054","article-title":"Real-world health-related quality of life and caregiver need in patients with metastatic hormone-sensitive and metastatic castration-resistant prostate cancer","volume":"40","author":"Boye","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.05.037_b0090","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.05.037_b0095","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.05.037_b0100","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/cancers14010147","article-title":"Assessment of health-related quality of life in patients with advanced prostate cancer-current state and future perspectives","volume":"14","author":"Kretschmer","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2025.05.037_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1240864","article-title":"Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews","volume":"13","author":"Leaning","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2025.05.037_b0110","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2025.05.037_b0115","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.05.037_b0120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2022.04.002","article-title":"Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021","volume":"82","author":"Gillessen","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.037_b0125","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.eururo.2020.04.061","article-title":"Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer from the PREVAIL trial","volume":"78","author":"Armstrong","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.037_b0130","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.05.037_b0135","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.05.037_b0140","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.05.037_b0145","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.05.037_b0150","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2025.05.037_b0155","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO.21.00643","article-title":"Metastatic prostate cancer: in search of more granularity","volume":"39","author":"Tewari","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.05.037_b0160","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.05.037_b0165","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41585-020-0289-9","article-title":"Does sequencing order of antiandrogens in prostate cancer matter?","volume":"17","author":"Maughan","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2025.05.037_b0170","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41391-020-0222-6","article-title":"Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"23","author":"Mori","year":"2020","journal-title":"Prostate Cancer Prostat Dis"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825003409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825003409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T01:46:52Z","timestamp":1786067212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825003409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0302283825003409"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.05.037","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.05.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}